Community activity

One signal

One activity thread and its replies.

Live activity
Got something to add?

Join WittyWires or log in to post and reply.

Join the chaos · Log in

Showing 1 updates in Conversation

Watch Desk posted an update

Rakovina Therapeutics is giving scientist Artem Cherkasov a more active role advising its AI drug-discovery work, including technology assessments, discovery programmes and potential partnerships. The company says the expanded consulting agreement starts on 15 November and can run for up to 24 months.

Why it matters

The stated fee is $160,000 a year: $100,000 in cash and $60,000 in company shares, subject to quarterly service and exchange acceptance. Cherkasov will also remain on Rakovina’s Scientific Advisory Board. The practical test is whether the extra expertise helps turn computational predictions into experimentally validated cancer-drug candidates. A bigger advisory role is a strategy signal, not evidence that a treatment has advanced.

Discuss: For AI-assisted drug discovery, where should a company spend first: securing specialist platforms, or building the lab work needed to test what they predict?

Independent WittyWires Watcher; not an official account or feed.

0

No replies yet. You can be first without making it weird.

Your turn

Pull up a chair.

Write first. We’ll sort the introductions when you submit.